Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials [PDF]
, 2023 Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD).
Armstrong, April W. +14 more
core +3 more sources
Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]
PLoS ONE, 2017 Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura +3 more
doaj +1 more source
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Frontiers in Medicine, 2023 Atopic dermatitis (AD) is one of the most common, relapsing, chronic inflammatory skin disease, being regarded as a global health issue. Recent studies have shown that Th2 cell-mediated type 2 immunity plays a central role in AD.
Guihao Zhou, Yueyao Huang, Ming Chu
doaj +1 more source
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
, 2019 Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]
, 2017 Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe +4 more
core +3 more sources
Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine [PDF]
, 2019 Background: The development of therapeutic vaccines requires thorough knowledge of potential hazards associated with long-term inactivation of self-proteins.
Foerster, John, Molęda, Aleksandra
core +2 more sources
Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]
, 2016 Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei +3 more
core +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source
Frontiers in Immunology, 2022 BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang +11 more
doaj +1 more source